In this Issue:
Ruxolitinib + lenalidomide for myelofibrosis
Warfarin-induced venous limb gangrene complicating cancer
Cyclosporin, levamisole + danazol for severe AA
High-dose dexamethasone, low-dose rituximab + cyclosporin for ITP
R-CHOP then radioimmunotherapy for early-stage DLBCL
Impact of comorbidities on OS in CML
Azacitidine vs. conventional care in elderly, new AML
Evaluating the QPCCC measure with haematological cancer survivors
Secondary APL: evolving characteristics and outcomes
Please login below to download this issue (PDF)